Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Deals Research and Development Strategies

Need For Partnering Won’t Change But Shape Might - BioJapan

While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.

Asia Pacific Research and Development Strategies

Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs

Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.

Deals Business Strategies

Takeda Offloads Emerging Market OTCs to Acino

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 
Deals Emerging Markets
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register